ITC rules against Korean botox maker in potentially precedent-setting case

摘要

The U.S. International Trade Commission this week ruled against a Korean maker of a generic form of botox and its U.S. partner in a decision some have warned could turn the court into an adjudicator of foreign disputes. The Section 337 case was brought by U.S. Botox maker Allergan and Medytox, a Korean manufacturer of a similar product, against Korean generic botox manufacturer Daewoong and its U.S. commercial partner, Evolus. The ITC conducts Section 337 investigations to determine whether unfair competition has occurred via imports that infringe on U.S. patent, copyright or trademarks.